BioDelivery Sciences International Inc. (BDSI) Stock Price Down 3.8%
BioDelivery Sciences International Inc. (NASDAQ:BDSI) shares were down 3.8% during trading on Monday . The company traded as low as $2.76 and last traded at $2.77, with a volume of 249,316 shares. The stock had previously closed at $2.88.
A number of research analysts have recently commented on BDSI shares. FBR & Co increased their target price on shares of BioDelivery Sciences International from $9.00 to $12.00 and gave the stock an “outperform” rating in a report on Wednesday, May 4th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a report on Friday, May 6th. Cantor Fitzgerald cut shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating and dropped their target price for the stock from $9.00 to $5.00 in a report on Wednesday, May 11th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $4.00 target price (down previously from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Finally, Janney Montgomery Scott reissued a “hold” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $8.25.
The stock’s 50-day moving average price is $2.55 and its 200 day moving average price is $2.91. The firm’s market capitalization is $149.12 million.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). During the same period last year, the business posted ($0.37) EPS. The firm earned $5 million during the quarter, compared to analysts’ expectations of $3.35 million. The company’s revenue was up 194.1% compared to the same quarter last year. Equities research analysts expect that BioDelivery Sciences International Inc. will post ($1.14) earnings per share for the current year.
In related news, Director William B. Stone sold 16,000 shares of BioDelivery Sciences International stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.57, for a total value of $41,120.00. Following the completion of the sale, the director now owns 122,675 shares of the company’s stock, valued at approximately $315,274.75. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.